STK11 and non-small cell lung carcinoma: Mutation of STK11 accounts for 20% of lung adenocarcinoma (LUAD), and confers peculiar characteristics to NSCLC, including disordered cellular metabolism, inactivation of stimulator of interferon genes (STING), and resistance to immunotherapy [4–7].